Full Press Release Details
Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND‑Enabling Studies at the San Antonio Breast Cancer Symposium.
ZYME
Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND‑Enabling Studies at the San Antonio Breast Cancer Symposium
Key Takeaway: Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND‑Enabling Studies at the San Antonio Breast Cancer Symposium
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers